ST吉药(300108) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥78,769,617.10, a decrease of 37.61% compared to the same period last year[5] - The net profit attributable to shareholders was -¥52,916,495.29, representing an 18.49% decline year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥47,347,265.17, down 30.10% from the previous year[5] - The company reported a 59% decrease in operating revenue for the year-to-date, totaling ¥238,000,505.51[8] - Total operating revenue for the period was ¥238,000,505.51, a decrease of 37.2% compared to ¥378,646,047.68 in the previous period[17] - Net profit for the period was a loss of ¥201,336,570.29, compared to a loss of ¥313,685,103.88 in the previous period, representing a 35.8% improvement[18] - Basic and diluted earnings per share were both -¥0.2164, an improvement from -¥0.4620 in the previous period[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,055,389,640.96, a decrease of 7.51% from the end of the previous year[5] - The company's total assets as of September 30, 2023, amount to CNY 2,055,389,640.96, a decrease from CNY 2,222,263,244.50 at the beginning of the year[14] - Current assets total CNY 480,940,843.85, down from CNY 540,104,453.27 at the start of the year[14] - The company's total liabilities are CNY 2,610,740,053.87, slightly up from CNY 2,588,572,723.56 at the beginning of the year[15] - The total equity attributable to shareholders of the parent company was -¥67,246,410.16, compared to ¥76,859,087.91 in the previous period[18] - The total liabilities and equity amounted to ¥2,055,389,640.96, a decrease from ¥2,222,263,244.50 in the previous period[18] Cash Flow - The cash flow from operating activities for the year-to-date was ¥2,835,537.70, a significant decrease of 80.13%[5] - Cash flow from operating activities generated a net amount of ¥2,835,537.70, down 80.2% from ¥14,267,213.02 in the previous period[19] - The net cash flow from investment activities was -7,189,465.47, a decrease of 2,335,079.46 compared to the previous period[20] - The total cash outflow from investment activities amounted to 25,179,707.15, with 22,500,000.00 related to other investment activities[20] - The net cash flow from financing activities was -355,895.58, a decrease of 11,903,922.46 compared to the previous period[20] - The total cash inflow from financing activities was 6,339,609.38, while the total cash outflow was 6,695,504.96[20] - The cash and cash equivalents at the end of the period were 18,607,210.48, down from 23,317,033.83 at the beginning of the period[20] Expenses - Sales expenses for the reporting period were ¥40,843,916.60, a reduction of 57% compared to the previous year[9] - Research and development expenses decreased by 60% to ¥6,129,842.08 due to management's decision to suspend operations of loss-making subsidiaries[9] - Research and development expenses were ¥6,129,842.08, a decrease of 37.5% from ¥9,804,273.34 in the previous period[17] - Financial expenses totaled ¥125,122,640.58, down 23.3% from ¥163,182,651.17 in the previous period[17] - Other income for the period was ¥179,882.49, significantly lower than ¥11,790,752.27 in the previous period[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,049[11] - The largest shareholder, Lu Zhongkui, holds 17.32% of the shares, with 115,334,302 shares pledged and frozen[11] Stock Information - The company announced the removal of the delisting risk warning for its stock, effective October 25, 2023[13] - The stock trading limit remains at 20% following the removal of the delisting risk warning[13] Audit Information - The company did not undergo an audit for the third quarter report[21]